Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Computer-aided diagnosis with a convolutional neural network algorithm for automated detection of urinary tract stones on plain X-ray.
Kobayashi M, Ishioka J, Matsuoka Y, Fukuda Y, Kohno Y, Kawano K, Morimoto S, Muta R, Fujiwara M, Kawamura N, Okuno T, Yoshida S, Yokoyama M, Suda R, Saiki R, Suzuki K, Kumazawa I, Fujii Y. Kobayashi M, et al. Among authors: kumazawa i. BMC Urol. 2021 Aug 5;21(1):102. doi: 10.1186/s12894-021-00874-9. BMC Urol. 2021. PMID: 34353306 Free PMC article.
Expression of oxytocin receptor in human pregnant myometrium.
Kimura T, Takemura M, Nomura S, Nobunaga T, Kubota Y, Inoue T, Hashimoto K, Kumazawa I, Ito Y, Ohashi K, Koyama M, Azuma C, Kitamura Y, Saji F. Kimura T, et al. Among authors: kumazawa i. Endocrinology. 1996 Feb;137(2):780-5. doi: 10.1210/endo.137.2.8593830. Endocrinology. 1996. PMID: 8593830
The role of N-terminal glycosylation in the human oxytocin receptor.
Kimura T, Makino Y, Bathgate R, Ivell R, Nobunaga T, Kubota Y, Kumazawa I, Saji F, Murata Y, Nishihara T, Hashimoto M, Kinoshita M. Kimura T, et al. Among authors: kumazawa i. Mol Hum Reprod. 1997 Nov;3(11):957-63. doi: 10.1093/molehr/3.11.957. Mol Hum Reprod. 1997. PMID: 9433921
Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04).
Futamura M, Ishihara K, Nagao Y, Ogiso A, Niwa Y, Nakada T, Kawaguchi Y, Ikawa A, Kumazawa I, Mori R, Kitazawa M, Hosono Y, Kuno M, Kawajiri M, Nakakami A, Takeuchi M, Morikawa A, Tokumaru Y, Katagiri Y, Asano Y, Mushika Y, Shimokawa T, Matsuhasih N. Futamura M, et al. Among authors: kumazawa i. Breast Cancer. 2023 Mar;30(2):293-301. doi: 10.1007/s12282-022-01425-2. Epub 2023 Jan 7. Breast Cancer. 2023. PMID: 36609911 Free PMC article. Clinical Trial.
24 results